ADAR1 Capital Management Reduces Stake in Inhibikase Therapeutics to 8.5%

On May 15, 2026, ADAR1 Capital Management, LLC and its affiliates filed a Schedule 13G/A regarding their holdings in Inhibikase Therapeutics, Inc. (IKT). The filing indicates a decrease in ownership for ADAR1 Capital Management GP, LLC, which now reports beneficial ownership of 11,832,998 shares, representing an 8.5% stake in the company. This is a reduction from the previously reported 12,692,387 shares and a 9.9% ownership level. The reporting persons include ADAR1 Capital Management, LLC, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger. The reported shares include common stock held directly by ADAR1 Partners, LP and ADAR1 SPV I, LP, as well as shares underlying milestone warrants. As the general partner and manager of these entities, ADAR1 Capital Management GP, LLC and Mr. Schneeberger may be deemed to have shared voting and dispositive power over the securities. The filing confirms that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.